THE FIRST HER2-TARGETED TREATMENT OF ITS KIND FOR PREVIOUSLY TREATED METASTATIC BREAST CANCER

KADCYLA contains 2 cancer-fighting agents in a single drug

KADCYLA is made up of two cancer-fighting agents:

  • The monoclonal antibody trastuzumab
  • A chemotherapy
KADCYLA is approved to treat HER2-positive (HER2+) breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with Herceptin® (trastuzumab) and a taxane.  Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.

Get started with KADCYLA

Take a closer look at KADCYLA treatment and the infusion process.

KADCYLA for HER2+ metastatic breast cancer

What are the potential benefits and risks with KADCYLA treatment?

Questions for your healthcare team

Being prepared will help you get the most out of your doctor’s appointments.